New Alzheimer’s drug deemed too pricey for UK’s state-run well being provider
Eisai-Biogen drug first remedy to gradual Alzheimer’s courseUK draft steering on price a blow after gradual take-up in U.S.Aug 22 (Reuters) – Alzheimer’s sufferers in Britain’s state-run well being provider are not